Obsidian Therapeutics Secures $160.5M Series C Funding for Advancement of OBX-115 Clinical Trials

Cambridge, MA, April 3, 2024 (Business Wire) -- Obsidian Therapeutics, Inc., a cutting-edge clinical-stage biotechnology company specializing in engineered cell and gene therapies, recently concluded a Series C financing round totaling $160.5 million, which was oversubscribed. This substantial funding was led by new investor Wellington Management, along with notable life science investors like Foresite Capital, Janus Henderson Investors, and Novo Holdings A/S, signaling strong support for the company's innovative endeavors. The funds raised will primarily support the clinical advancement of OBX-115, including ongoing trials targeting patients with metastatic melanoma and non-small cell lung cancer.

Read full article here.